Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   BioPharma   /   Xoma

BioPharma« Terug naar discussie overzicht

Xoma

Volgen
450 Posts
Pagina: «« 1 ... 13 14 15 16 17 ... 23 »» | Laatste | Omlaag ↓
  1. gustaaf1e 2 januari 2013 13:33
    t.k. voor volgers en andere geïnteresseerden.
    G

    (RTTNews.com) - XOMA Corp. ( XOMA ), a leader in the discovery and development of therapeutic antibodies, Monday said it has selected active non-infectious anterior scleritis, which is the inflammation of the sclera, as the third indication in its gevokizumab proof-of-concept program.

    The company is working with the National Eye Institute on designing the protocol for this study.

    Gevokizumab (XOMA 052) is a potent monoclonal antibody with the potential to treat patients with a wide variety of inflammatory and other diseases. It has been studied in nearly 500 patients, with around 300 patients on treatment for six months, and has been shown to be well-tolerated.

    For comments and feedback: contact editorial@rttnews.com

    www.rttnews.com
  2. gustaaf1e 21 februari 2013 22:29
    BERKELEY, Calif., Feb. 21, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that management is scheduled to present at three upcoming investor conferences. The details are as follows:

    RBC Capital Markets Global Healthcare Conference on Tuesday, February 26, 2013 at 11:30 a.m. ET at The New York Palace Hotel
    Cowen and Company 33rd Annual Health Care Conference on Wednesday, March 6, 2013 at 8:40 a.m. ET at The Boston Marriott Copley Place
    25th Annual ROTH Conference on Monday, March 18, 2013 at 2:00 p.m. PT at The Ritz-Carlton, Laguna Niguel
    Live audio webcasts of the presentations can be accessed through the Investors and Media section of XOMA's website at investors.xoma.com/events.cfm. Archived versions of the webcast will be available via replay for 30 days following the presentation.

    G
  3. gustaaf1e 1 maart 2013 10:13
    Xoma

    More on Stockpickr

    8 Stocks Under $10 Moving Higher


    Another under-$10 name that's starting to trend into range of triggering a near-term breakout trade is Xoma(XOMA_), which is engaged in the discovery, development and manufacture of therapeutic antibodies and other agents designed to treat inflammatory, autoimmune, infectious and oncological diseases. This stock hasn't done much so far in 2013, with shares trading virtually flat.

    If you take a look at the chart for XOMA, you'll notice that this stock has been trading in a tight consolidation pattern for the last two months, with shares moving between $2.37 on the downside and $3 a share on the upside. Shares of XOMA are just starting to push back above its 50-day moving average of $2.68 a share, and it's quickly moving within range of breaking out above a key downtrend line.

    Market players should now look for long-biased trades in XOMA if it manages to break out above some near-term overhead resistance levels at $2.83 to $3 a share and then once it takes out more resistance at $3.10 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 549,387 shares. If that breakout triggers soon, then XOMA will set up to re-test or possibly take out its next major overhead resistance levels at $3.44 to $4 a share.

    Traders can look to buy XOMA off any weakness to anticipate that breakout and simply use a stop that sits right around some near-term support levels at $2.46 to $2.37 a share. One could also buy XOMA off strength once it takes out those breakout levels with volume and then simply use a stop that sits just below its 50-day moving average of $2.68 a share. I would add to either position once this stock clears $3 to $3.10 with strong volume.

    G
  5. gustaaf1e 9 mei 2013 16:34

    +15 %
    G

    May 8, 2013

    XOMA Highlights Recent Achievements and Reports Financial Results for First Quarter 2013



    BERKELEY, Calif., May 8, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today reported its operational highlights and financial results for the quarter ended March 31, 2013.
    • Announced encouraging interim results from gevokizumab Phase 2 study for moderate to severe acne vulgaris, the first indication in a program of three proof-of-concept ("POC") studies for gevokizumab. The data generated supports further development in this indication.
    • Focused on advancing the gevokizumab Phase 3 EYEGUARD™ pivotal studies in non-infectious uveitis ("NIU").
    • Advanced the second gevokizumab Phase 2 POC study in patients with erosive osteoarthritis of the hand ("EOA").
    • Appointed Tom Klein as Vice President, Chief Commercial Officer, a newly created position.

    XOMA reported total revenues of $9.5 million in the first quarter of 2013, compared with $9.9 million in the corresponding period of 2012. The small decrease in 2013 revenues was due primarily to a reduction in contract and other revenue associated with NIAID contracts. For the quarter ended March 31, 2013, XOMA had a net loss of $24.9 million (or $0.30 per share), compared with a net loss of $30.4 million, or $0.69 per share, for the quarter ended March 31, 2012. The net loss for the first quarters of 2013 and 2012 included a non-cash charge of $12.8 million (or $0.16 per share) and $14.4 million (or $0.33 per share), respectively, both of which were related to the revaluation of contingent warrant liabilities, which resulted primarily from the appreciation of XOMA's stock price. Excluding these non-cash charges, net loss in the first quarters of 2013 and 2012 was $12.0 million (or $0.15 per share) and $16.0 million (or $0.36 per share), respectively.

    "We focused our first quarter activities on advancing the gevokizumab Phase 3 pivotal studies in patients with NIU and on executing our second gevokizumab proof-of-concept study in patients with erosive osteoarthritis of the hand. Based upon the enrollment in the EOA study, we anticipate receiving the top-line data around Labor Day," stated John Varian, Chief Executive Officer of XOMA. "In addition, we are very pleased with the initial results from our first gevokizumab Phase 2 POC study in patients with moderate to severe inflammatory acne which we announced early in the quarter. We believe the data establishes that IL-1 beta plays a role in moderate to severe inflammatory acne, and the feedback from key opinion leaders in dermatology supports further development. We look forward to the results from our EOA study to inform our decision as to our next Phase 3 indication."

    "The second highlight of our first quarter was attracting Tom Klein to join XOMA as our first Chief Commercial Officer," Mr. Varian continued. "We are in the position to begin planning for gevokizumab's future as a commercial product, and Tom's expertise in marketing pharmaceutical products to the specialist provider will be invaluable as we select our next Phase 3 indication and near the completion of our EYEGUARD program."

    Research and development expenses for the first quarter of 2013 were $16.6 million, compared with $15.8 million in the corresponding period of 2012. General and administrative expenses were $4.1 million in the first quarter of 2013, a 12 percent reduction from the $4.7 million incurred in the first quarter of 2012. As a result of the company's streamlining activities announced in January 2012, XOMA recorded a charge of $3.8 million during the first quarter of 2012.

    On March 31, 2013, XOMA had cash, cash equivalents, and short-term investments of $70.4 million. The Company ended December 31, 2012, with cash, cash equivalents, and short-term investments of $85.3 million.

    2013 Guidance

    The company reconfirmed its anticipated cash used in ongoing operating activities during 2013 will be approximately $50 million, primarily reflecting the costs associated with conducting the EYEGUARD-A, EYEGUARD-B and EYEGUARD-C Phase 3 clinical trials. This guidance initially was provided on March 12, 2013.

    Investor Conference Call and Webcast

    XOMA will host a conference call and webcast today, May 8, 2013, at 4:30 p.m. ET. The webcast can be accessed via the Investors section of XOMA's website at investors.xoma.com/events.cfm and will be available for replay until close of business on August 8, 2013.

    Telephone numbers for the live audiocast are 877-369-6589 (U.S./Canada) and 408-337-0122 (international). A telephonic replay will be available beginning approximately two hours after the conclusion of the call until close of business on May 15, 2013. Telephone numbers for the replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international), passcode 42348170.

    About Gevokizumab

    Gevokizumab is a potent monoclonal antibody with unique allosteric modulating properties and the potential to treat patients with a wide variety of inflammatory and other diseases. Gevokizumab binds strongly to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine that has been shown to be involved in non-infectious uveitis, including Behçet's uveitis, cardiovascular disease, and other auto-inflammatory diseases. By binding to IL-1 beta, gevokizumab inhibits the activation of the IL-1 receptor, thereby modulating the cellular signaling events that produce inflammation. Gevokizumab has been studied in over 500 patients, with approximately 300 patients on treatment for six months, and has been shown to be well-tolerated. Information about gevokizumab clinical studies can be found at www.clinicaltrials.gov.
  7. gustaaf1e 26 juni 2013 22:25
    XOMA Corporation ( XOMA ) recently announced that its partner, Les Laboratoires Servier, a French pharmaceutical company, has initiated an independent proof-of-concept (POC) clinical program on gevokizumab. The POC program will be evaluating the safety and efficacy of gevokizumab in several therapeutics areas.

    XOMA has collaborated with privately held Servier for the development of gevokizumab, an interleukin-1 beta (IL-1 beta) modulating antibody. XOMA and Servier are evaluating the use of gevokizumab in a number of indications including non-infectious uveitis (NIU) involving the intermediate and/or posterior portion of the eye and Behçet's uveitis. The potential of the candidate to improve symptoms of pain, physical function and other abnormalities in patients suffering from erosive osteoarthritis of the hand is also being evaluated.

    The first study under the POC program on gevokizumab will be in patients suffering from polymyositis/dermatomyositis.

    We note that XOMA had initiated a similar POC program on gevokizumab in Nov 2011 for indications like moderate-to-severe inflammatory acne vulgaris, erosive inflammatory osteoarthritis of the hand, and non-anterior scleritis.

    In Jan 2013, XOMA reported preliminary top-line data from a phase II POC study in the inflammatory acne indication. Preliminary results from the study showed that the 0.6mg/kg dose of gevokizumab demonstrated a significant reduction of 19 in mean inflammatory lesion count compared to a reduction of 13 in patients under the placebo group on day 42. The difference was maintained throughout the study.

    XOMA recently initiated a pilot study to evaluate the use of gevokizumab in patients suffering from acute inflammatory pyoderma gangrenosum (PG). XOMA intends to enrol up to 8 patients suffering from acute inflammatory PG for the study. Their disease is characterized by recently developed active ulcers apart from ulcer-related pain.

    Gevokizumab is the lead candidate at XOMA. The company has progressed well so far with the candidate. We expect investor focus to stay on gevokizumab going forward.

    Read more: www.nasdaq.com/article/new-study-on-x...
  8. gustaaf1e 3 juli 2013 16:39
    XOMA to Present at the JMP Securities Healthcare Conference

    BERKELEY, Calif., July 2, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that Dr. Paul Rubin, the company's Senior Vice President, Research and Development and Chief Medical Officer, is scheduled to present at JMP Securities 2013 Healthcare Conference on July 9, 2013 at 3:30 p.m. ET.

    A live audio webcast of the presentation can be accessed in the Investors and Media section of XOMA's website at investors.xoma.com/events.cfm. An archived version of the webcast will be available via replay for 30 days following the presentation.

    G
  9. gustaaf1e 3 juli 2013 16:40

    July 3, 2013

    XOMA Transfers Perindopril Franchise Rights to Symplmed

    BERKELEY, Calif., July 3, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it has transferred U.S. development and commercialization rights to the perindopril franchise to Symplmed Pharmaceuticals, LLC ("Symplmed"). Under the terms of the agreement, XOMA will receive an equity position in Symplmed and up to double-digit royalties on sales of the fixed-dose combination ("FDC") containing perindopril arginine and amlodipine besylate, if it is approved by the U.S. Food and Drug Administration ("FDA"). Symplmed will, under a sublicense agreement, immediately assume U.S. marketing responsibilities for ACEON® (perindopril erbumine), and XOMA will continue to manage and be reimbursed for sales and distribution within its established commercial infrastructure.

    Symplmed was founded by former XOMA employees, Erik Emerson and Jeffrey Feldstein, MD, who serve as Chief Executive Officer and Chief Medical Officer, respectively, and Dr. August J. Troendle. Both Mr. Emerson and Dr. Feldstein have significant experience developing and marketing FDA-approved cardiovascular therapeutics and have been directly involved with the ACEON commercialization activities. In addition, Mr. Emerson and Dr. Feldstein managed the 837-patient Phase 3 PATH trial (Perindopril Amlodipine for the Treatment of Hypertension), which demonstrated that the FDC of perindopril arginine combined with amlodipine besylate is statistically significantly superior to either compound alone in reducing both sitting diastolic and sitting systolic blood pressure after six weeks of treatment. Servier markets the FDC product, COVERAM®, in 91 countries outside the U.S. Symplmed intends to complete the New Drug Application for the FDC and submit it to the FDA for review by year-end 2013. Symplmed will be responsible for all future FDC development costs, and XOMA will have no further financial obligations related to the FDC product or Symplmed's operations.

    "Our partner, Servier, and we recognize the importance of this valuable franchise. Erik and Jeff have demonstrated strong dedication to the perindopril franchise and are leaving XOMA to launch Symplmed and move the franchise forward in a focused manner. This structure provides XOMA the opportunity to share in their success, while retaining our focus on developing innovative therapeutic options for the specialist prescriber under the leadership of Tom Klein, our newly appointed Chief Commercial Officer," commented John Varian, Chief Executive Officer of XOMA. "The experience the XOMA team gained by establishing a commercial infrastructure backbone will serve the company well as we move closer to commercializing novel therapeutics discovered by XOMA's scientists."

    G
  11. gustaaf1e 22 juli 2013 17:54

    July 22, 2013

    XOMA Completes Enrollment in Phase 2 Proof-of-Concept Gevokizumab Trial in Patients With Erosive Osteoarthritis of the Hand

    BERKELEY, Calif., July 22, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today confirmed it has completed patient enrollment in the Company's Phase 2 proof-of-concept (POC) study designed to evaluate the potential for gevokizumab to improve pain symptoms, physical function and structural abnormalities in patients with active inflammatory, erosive osteoarthritis of the hand (EOA) and elevated C-reactive protein (CRP) levels. XOMA's study enrolled approximately 90 patients who were randomized 2:1 to receive 60mg of gevokizumab dosed subcutaneously once monthly or placebo. The study was designed and powered to detect a significant improvement from baseline versus placebo in the mean Australian/Canadian Hand Osteoarthritis Index (AUSCAN™) pain score in the target hand at Day 84. The study also is capturing multiple outcome measures, including pain, stiffness, physical function, X-ray, radiographic and MRI changes, as well as changes in CRP and concomitant acetaminophen use, at three and six months. The Company anticipates having preliminary top-line data for the AUSCAN score in October.

    XOMA also provided an update on the EOA study in patients with non-elevated CRP. This study was opened for enrollment in May, and investigators have enrolled approximately 40 patients of the targeted 90 who had qualified for the original EOA study with the exception that they did not have elevated CRP levels. This supplemental study will help inform the design of the potential Phase 3 studies of gevokizumab in EOA.

    G
  14. gustaaf1e 11 september 2013 14:47
    Inmiddels ook alles in 2 porties (op $5.30 en $4.50)verkocht en weer een portie gekocht.
    En straks weer presentatie.
    G

    September 5, 2013

    XOMA to Present at the Morgan Stanley Healthcare Conference

    BERKELEY, Calif., Sept. 5, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today Paul Rubin, MD, the Company's Senior Vice President, Research and Development and Chief Medical Officer, is scheduled to present at the Morgan Stanley Healthcare Conference at 11:45 a.m., on September 11, 2013, at the Grand Hyatt Hotel in New York City.

    A live audio webcast of the presentation can be accessed in the Investors and Media section of XOMA's website at investors.xoma.com/events.cfm. An archived version of the webcast will be available via replay for 30 days following the presentation
450 Posts
Pagina: «« 1 ... 13 14 15 16 17 ... 23 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
THEON INTERNAT 14,900 +1,14 +8,28%
AMG Critical Materials N.V. 14,530 +0,47 +3,34%
Aperam 29,020 +0,70 +2,47%
UMG 26,980 +0,60 +2,27%
AZERION 1,670 +0,03 +1,83%
NX FILTRATION 2,945 +0,05 +1,55%
PostNL 1,037 +0,02 +1,47%
JUST EAT TAKEAWAY 12,105 +0,15 +1,25%
Fagron 19,560 +0,20 +1,03%
PROSUS 38,880 +0,39 +1,01%
Arcadis 54,450 +0,50 +0,93%
NN Group 44,290 +0,40 +0,91%
ABN AMRO BANK N.V. 16,385 +0,15 +0,89%
Heineken 67,920 +0,60 +0,89%
BAM 4,164 +0,03 +0,82%
OCI 10,875 +0,09 +0,79%
Kendrion 10,320 +0,08 +0,78%
INPOST 16,100 +0,12 +0,75%
JDE PEET'S 16,200 +0,12 +0,75%
UNILEVER PLC 56,380 +0,40 +0,71%
VASTNED 28,300 +0,20 +0,71%
KPN 3,532 +0,02 +0,60%
Accsys 0,506 +0,00 +0,60%
CTP 16,340 +0,08 +0,49%
Ahold Delhaize 35,150 +0,13 +0,37%
ING 15,968 +0,05 +0,30%
SHELL PLC 31,980 +0,07 +0,20%
ASR Nederland 47,910 +0,09 +0,19%
SBM Offshore 18,310 +0,03 +0,16%
Aegon 6,378 +0,01 +0,13%
Avantium 1,740 +0,00 +0,12%
ASCX 1.262,21 +1,19 +0,09%
ACOMO 18,080 0,00 0,00%
Nedap N.V. 59,200 0,00 0,00%
Philips Koninklijke 26,590 0,00 0,00%
RENEWI 9,650 0,00 0,00%
Wolters Kluwer 176,550 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
EBUSCO HOLDING 0,770 -0,04 -4,60%
ALLFUNDS GROUP 4,874 -0,18 -3,49%
TomTom 4,022 -0,11 -2,57%
BESI 115,400 -2,85 -2,41%
IMCD 147,750 -3,60 -2,38%
AALBERTS NV 33,680 -0,70 -2,04%
ADYEN NV 1.553,200 -32,20 -2,03%
CM.COM 6,940 -0,13 -1,84%
Akzo Nobel 56,440 -1,04 -1,81%
ForFarmers 3,335 -0,06 -1,77%
Fugro 14,210 -0,25 -1,73%
ASML 703,000 -12,30 -1,72%
TKH 35,680 -0,58 -1,60%
ASMI 545,600 -8,80 -1,59%
Basic-Fit 23,320 -0,36 -1,52%
RANDSTAD NV 41,550 -0,58 -1,38%
WDP 20,080 -0,28 -1,38%
FASTNED 20,350 -0,25 -1,21%
Flow Traders 23,980 -0,28 -1,15%
Corbion 22,140 -0,22 -0,98%
Alfen N.V. 14,140 -0,14 -0,95%
ArcelorMittal 27,360 -0,25 -0,91%
Galapagos 22,080 -0,20 -0,90%
Sif Holding 11,980 -0,10 -0,83%
HEIJMANS KON 31,650 -0,25 -0,78%
SIGNIFY NV 21,000 -0,14 -0,66%
Brunel 9,330 -0,06 -0,64%
Air France-KLM 8,200 -0,05 -0,61%
Pharming 0,831 -0,01 -0,60%
Van Lanschot Kempen NV 47,150 -0,25 -0,53%
Vopak 44,500 -0,22 -0,49%
DSM FIRMENICH AG 95,440 -0,44 -0,46%
NSI 22,000 -0,10 -0,45%
Eurocommercial Properties 23,750 -0,10 -0,42%
Sligro 10,680 -0,04 -0,37%
AMX 840,01 -2,72 -0,32%
Wereldhave 14,780 -0,04 -0,27%
B&S Group SA 4,165 -0,01 -0,12%
AEX 924,10 -1,03 -0,11%
RELX 48,460 -0,04 -0,08%
EXOR NV 92,100 -0,05 -0,05%
vlag naam koers verschil relatief verschil
AEX 924,10 -1,03 -0,11%
AEX GR 3.624,62 -4,06 -0,11%
Germany40^ 21.902,42 0,00 0,00%
FTSE 100 8.695,32 -31,96 -0,37%
Europe50^ 5.325,40 -31,23 -0,58%
US30^ 44.342,20 -399,80 -0,89%
Nasd100^ 21.508,40 -251,10 -1,15%
US500^ 6.029,92 -53,41 -0,88%
Japan225^ 38.404,40 -572,50 -1,47%
VD-NEW 17,17 +1,04 +6,44%
#/^ Index indications calculated real time, zie disclaimer